ATOS — ATOSSA THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1488039 ·
Last close
$1.90
Market Cap
$18.96M
52W High
$14.85
52W Low
$1.70
ADV30
81,256
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -5,899,000 | -5,638,000 | 26,448,000 | 20,574,000 | 4,709,000 |
| Jun 2026 | 0 | — | -8,694,000 | -8,491,000 | 32,281,000 | 26,094,000 | 5,451,000 |
| Mar 2026 | 0 | — | -9,870,000 | -9,589,000 | 37,943,000 | 31,718,000 | 7,457,000 |
| Dec 2025 | 0 | — | -11,436,000 | -10,937,000 | 47,608,000 | 41,299,000 | 8,255,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-35,284,000
Investing CF
$-7,000
Financing CF
$0
CapEx
$-23,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.63
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-270,280,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-35,899,000
Pretax Income TTM
$-34,655,000
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -37,141,000 | -34,770,000 | 47,608,000 | 8,255,000 | 39,353,000 | -29,762,000 |
| Dec 2024 | 0 | -27,621,000 | -25,504,000 | 76,444,000 | 4,967,000 | 71,477,000 | -21,030,000 |
| Dec 2023 | 0 | -31,377,000 | -30,094,000 | 96,252,000 | 5,236,000 | 91,016,000 | -20,941,000 |
| Dec 2022 | 0 | -27,691,000 | -26,960,000 | 123,532,000 | 5,568,000 | 117,964,000 | -20,760,000 |
TTM Snapshot
Revenues TTM
$1,548,000
NetIncome TTM
$-37,709,000
OpCashFlow TTM
—
Assets (Latest)
$32,281,000
Forward EPS
$-3.30
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.00 · spot: $1.81 · call volume: 27 · put volume: 7
Expected Move to 2027-01-15:
±$0.68
(37.29%) —
implied range
$1.14 –
$2.49
· ATM straddle on $2.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EDSA | Edesa Biotech, Inc. | $18.90M | $1.96 | — |
| CELU | Celularity Inc | $18.53M | $0.57 | — |
| IGC | IGC Pharma, Inc. | $19.43M | $0.19 | — |
| COCP | Cocrystal Pharma, Inc. | $19.46M | $1.01 | — |
| PVCT | PROVECTUS BIOPHARMACEUTICALS, INC. | $17.90M | $0.04 | — |
News headlines (Yahoo Finance, 1h cache)
Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
2026-11-10 13:15 · Yahoo
Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today
2026-10-19 12:00 · Yahoo
Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value
2026-10-09 12:00 · Yahoo
Atossa plans shareholder stake in potential PRV proceeds
2026-09-30 17:18 · Yahoo
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
2026-09-29 12:00 · Yahoo
Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging
2026-09-24 12:00 · Yahoo
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
2026-08-07 12:45 · Yahoo
Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer
2026-07-28 12:30 · Yahoo
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers
2026-07-21 12:30 · Yahoo
ATOS: Raises up to $16.5 Million in Registered Direct Offering
2026-07-01 13:08 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.